This chapter presents a series of case studies with multiple choice questions and answers on second-line treatment of ovarian cancer. It commences with a discourse on reasonable subsequent management strategies of cancer, and ends with a phase III trial that compared the administration of cytotoxic chemotherapy with or without bevacizumab in platinum-resistant ovarian cancer, and three different cytotoxic regimens. The chapter also discusses regarding the clinical utility of secondary surgical cytoreduction in the clinical setting and second-line management strategies of ovarian cancer.